Recently, five immune checkpoint inhibitors blocking PD-1 or PD-L1 were approved by the US Food and Drug Administration (FDA) in the management of advanced BC, which represents new therapeutic opportunities [10]. This evidence concerns the gene PDCD1 and breast cancer.